ArticleFrontiers in oncology2026
Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MEX3A is an RNA-binding protein implicated in post-transcriptional regulation; however, its role across cancers, particularly in chromophobe renal cell carcinoma (chRCC), remains unclear. Methods: We performed a comprehensive pan-cancer analysis using TCGA and related databases to evaluate MEX3A expression, prognostic significance, immune associations, genomic alterations, and drug sensitivity. Functional experiments were conducted in chRCC cell lines. Results: MEX3A was significantly upregulated in multiple cancers and was associated with poor prognosis. Its expression correlated with immune cell infiltration, immune checkpoint molecules, tumor mutational burden, and microsatellite instability. High MEX3A expression was linked to reduced drug sensitivity. Functional assays confirmed its oncogenic role in chRCC. Conclusion: MEX3A serves as a potential prognostic biomarker and therapeutic target in chRCC and may play a critical role in tumor progression and immune regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.